BIOCRYST PHARMACEUTICALS INC Contracts & Agreements

158 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Drug/Drug Candidate
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2020
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 22, 2024)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
2024
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2023
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 24, 2023)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
2023
Drug/Drug Candidate
BIOCRYST PHARMACEUTICALS INC
2023
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2022
Amendment, dated August 10, 2022, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2022
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 18, 2022)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
2022
the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO(berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2022
the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO(berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
EX-10.14 EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104
BIOCRYST PHARMACEUTICALS INC
2022
EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104
BIOCRYST PHARMACEUTICALS INC
2022
EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT
Employment Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2021
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT
Employment Agreements
BIOCRYST PHARMACEUTICALS INC
2021
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT
Employment Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2021
Amendment, dated August 27, 2021, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services
BIOCRYST PHARMACEUTICALS INC
2021
Separation Agreement and Release, dated August 8, 2021, by and between BioCryst Pharmaceuticals, Inc. and Megan Sniecinski
Separation Agreements
BIOCRYST PHARMACEUTICALS INC
2021
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 1, 2021)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2021
BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated as of April 1, 2021)
Stock Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2021
BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2021
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2021
BioCryst Pharmaceuticals, Inc. Annual Incentive Plan, effective as of December 16, 2020
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2020
THIRD aMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT
Credit Agreements
BIOCRYST PHARMACEUTICALS INC
2020
Amendment, dated August 31, 2020, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2020
Underwriting Agreement, dated May 27, 2020, by and among BioCryst Pharmaceuticals, Inc. and J.P. Morgan Securities LLC and Piper Sandler & Co., as representatives of the...
Underwriting Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2020
Form of Warrant to Purchase Common Stock, dated June 1, 2020
Warrant Agreements
BIOCRYST PHARMACEUTICALS INC
2020
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of March 19, 2020)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2020
BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated as of March 19, 2020)
Stock Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2020
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2020
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2020
Description of Common Stock
Stock Agreements
BIOCRYST PHARMACEUTICALS INC
2020
Drug/Drug Candidate
BIOCRYST PHARMACEUTICALS INC
2020
Form of Warrant to Purchase Common Stock, dated November 21, 2019
Warrant Agreements
BIOCRYST PHARMACEUTICALS INC
2019
Securities Purchase Agreement, dated November 19, 2019, among BioCryst Pharmaceuticals, Inc., Baker Brothers Life Sciences, L.P. and 667, L.P
Purchase Agreements
BIOCRYST PHARMACEUTICALS INC
2019
Underwriting Agreement, dated November 13, 2019, by and between BioCryst Pharmaceuticals, Inc. and J.P. Morgan Securities LLC, as representative of the underwriters named in...
Underwriting Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2019
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2019
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2019
Amendment dated as of September 23, 2019 to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2019
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2019
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as Amended and Restated April 12, 2019)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
2019
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2019
Financial Statements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Financial Statements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Financial Statements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Financial Statements
BIOCRYST PHARMACEUTICALS INC
2018
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as Amended and Restated September 17, 2018)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Contract dated as of September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Centers for Disease Control and Prevention
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Underwriting Agreement, dated August 1, 2018, by and among BioCryst Pharmaceuticals, Inc. and J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the underwriters...
Underwriting Agreements
BIOCRYST PHARMACEUTICALS INC
2018
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2018
Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2018
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2017
Underwriting Agreement, dated September 12, 2017, by and among BioCryst Pharmaceuticals, Inc., J. P. Morgan Securities LLC and Barclays Capital Inc., as representatives of the...
Underwriting Agreements
BIOCRYST PHARMACEUTICALS INC
2017
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as Amended and Restated April 3, 2017)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
2017
Registration Rights Agreement, dated March 15, 2017, by and between BioCryst Pharmaceuticals, Inc., 667, L.P., and Baker Brothers Life Sciences, L.P
Registration Rights Agreements
BIOCRYST PHARMACEUTICALS INC
2017
BIOCRYST PHARMACEUTICALS, INC. 5,294,118 Shares of Common Stock (par value $0.01 per share) Underwriting Agreement
Underwriting Agreements
BIOCRYST PHARMACEUTICALS INC
2017
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS, IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2016
CREDIT AND SECURITY AGREEMENT
Credit Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
MD
2016
Statement of Work BioCryst Pharmaceuticals Contract HHSO100201500007C BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2016
Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked *** and has been filed separately with the Securities and Exchange Commission pursuant to a...
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2015
1. DEFINITIONS AND INTERPRETATION
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2015
Pursuant to 17 CFR 20.24b-2, confidential information has been omittedin places marked "***" and has been filed separately with the Securities and Exchange Commission pursuant to...
Exchange Agreements
BIOCRYST PHARMACEUTICALS INC
2015
BIOCRYST PHARMACEUTICALS, INC. STANDARD STOCK OPTION AGREEMENT WITNESSETH:
Stock Agreements
BIOCRYST PHARMACEUTICALS INC
2015
BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2015
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2014
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
BIOCRYST PHARMACEUTICALS, INC. 10,000,000 Shares of Common Stock (par value $0.01 per share) Underwriting Agreement
Underwriting Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2014
BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED March 8, 2014) ARTICLE ONE GENERAL PROVISIONS
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
BIOCRYST PHARMACEUTICALS, INC. EMPLOYEE STOCK PURCHASE PLAN (Amended and Restated March 8, 2014)
Stock Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
Exhibit A (ProprietaryInformation and Inventions Agreement) EMPLOYEES PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2014
Supplies/Services
BIOCRYST PHARMACEUTICALS INC
2014
Option/Increment Description
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
Contract No. HHSN272201300017C Modification No. 2
Modification Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
CONTRACT TABLE OF CONTENTS
BIOCRYST PHARMACEUTICALS INC
2013
BIOCRYST PHARMACEUTICALS, INC. 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreements
BIOCRYST PHARMACEUTICALS INC
2013
FOURTH AMENDMENT TO LEASE AGREEMENT
Lease Agreements
BIOCRYST PHARMACEUTICALS INC
2013
MUTUAL TERMINATION AND RELEASE AGREEMENT
Termination Agreements
BIOCRYST PHARMACEUTICALS INC
2012
EXECUTION COPY MERGER AGREEMENT BY AND AMONG PRESIDIO PHARMACEUTICALS, INC., S SUB, INC., BIOCRYST PHARMACEUTICALS, INC. AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, SOLELY IN ITS...
Merger Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2012
INVESTOR FINANCING AGREEMENT by and among BIOCRYST PHARMACEUTICALS, INC. and THE INVESTORS LISTED ON SCHEDULE 1 Dated as of October 17, 2012 TABLE OF CONTENTS
Financing Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2012
VOTING AND POST-CLOSING LOCK-UP AGREEMENT
Voting Agreements
BIOCRYST PHARMACEUTICALS INC
2012
SIDE AGREEMENT TO INVESTOR FINANCING AGREEMENT
Financing Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2012
Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked * * * and has been filed separately with the Securities and Exchange Commission pursuant...
Exchange Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2012
BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED MARCH 29, 2012) ARTICLE ONE GENERAL PROVISIONS
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2012
BIOCRYST PHARMACEUTICALS, INC. EMPLOYEE STOCK PURCHASE PLAN (Amended and Restated March 29, 2012)
Stock Agreements
BIOCRYST PHARMACEUTICALS INC
2012
BioCryst Pharmaceuticals, Inc. Annual Incentive Plan Communication Summary for Participants Effective March 9, 2012 BioCryst Pharmaceuticals, Inc. Annual Incentive Plan Effective...
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2012
AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN BIOCRYST PHARMACEUTICALS, INC. AND MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED
License Agreements
BIOCRYST PHARMACEUTICALS INC
2012
FIFTH AMENDMENT AGREEMENT
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2012
EX-101 INSTANCE DOCUMENT
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2011
BioCryst Pharmaceuticals, Inc. 4505 Emperor Blvd, Suite 200 Durham, NC 27703 ###-###-#### phone ###-###-#### fax www.biocryst.com
BIOCRYST PHARMACEUTICALS INC
2011
BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED FEBRUARY 17, 2011)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2011
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2011
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2011
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2011
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
2011
Financial Statements
BIOCRYST PHARMACEUTICALS INC
2010
Signature Date
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2010
THIRD AMENDMENT AGREEMENT
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2010
5,000,000 Shares BIOCRYST PHARMACEUTICALS, INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT
Underwriting Agreements
BIOCRYST PHARMACEUTICALS INC
2009
Name TitleWilliam P. Sheridan, M.D. Chief Medical Officer, Principal InvestigatorElliott Berger, Ph.D. Sr. Vice President, Regulatory AffairsWalter G. Gowan, Ph.D. Vice President...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2009
FIRST AMENDMENT TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
License Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2009
SEVERANCE AGREEMENT AND GENERAL RELEASE
Severance Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2009
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 1 2. AMENDMENT/MODIFICATION NO: 3. EFFECTIVE DATE 4. REQUISITION/PURC 5. PROJECT NO. (If...
Development Agreements
BIOCRYST PHARMACEUTICALS INC
2008
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2008
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2008
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2008
EX-10.1 ANNUAL INCENTIVE PLAN
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2008
EX-10.2 EXECUTIVE RELOCATION POLICY
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2008
EX-10.3 AMENDMENT TO EMPLOYMENT LETTER AGREEMENT
Employment Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2008
EX-10.4 FORM OF NOTICE OF GRANT NON-EMPLOYEE DIRECTOR
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2008
EX-10.5 FORM OF NOTICE OF GRANT OF STOCK OPTION
Stock Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2008
EX-10.6 AMENDMENT #3 TO THE AGREEMENT
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2008
BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (formerly the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan)
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2007
Page 2 of 27
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2007
STATE OF ALABAMA ) SHELBY COUNTY ) THIRD AMENDMENT TO LEASE AGREEMENT
Lease Agreements
BIOCRYST PHARMACEUTICALS INC
2007
STOCK AND WARRANT PURCHASE AGREEMENT
Warrant Agreements
BIOCRYST PHARMACEUTICALS INC
2007
FORM OF WARRANT
Warrant Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2007
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2007
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2007
EX-10.12 AMENDED AND RESTATED EMPLOYMENT LETTER AGREEMENT
Employment Agreements
BIOCRYST PHARMACEUTICALS INC
2007
BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (formerly the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan) (AMENDED AND RESTATED EFFECTIVE MARCH 7, 2006) ARTICLE ONE...
Bonus & Incentive Agreements
BIOCRYST PHARMACEUTICALS INC
2006
License Agreement
License Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2006
Development and License Agreement
License Agreements
BIOCRYST PHARMACEUTICALS INC
2005
Stock Purchase Agreement
Stock Agreements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
CA
2005
Nomination and Observer Agreement
BIOCRYST PHARMACEUTICALS INC
Biotechnology
CA
2005
LICENSE AGREEMENT BETWEEN ALBERT EINSTEIN COLLEGE OF MEDICINE, INDUSTRIAL RESEARCH, LTD AND BIOCRYST PHARMACEUTICALS, INC. Statement 1 1. Definitions 2 1.01 Field 2 1.02 Agreement...
Termination Agreements
BIOCRYST PHARMACEUTICALS INC
2005
Stock Purchase Agreement
Stock Agreements
BIOCRYST PHARMACEUTICALS INC
2005
Placement Agency Agreement
Agency Agreements
BIOCRYST PHARMACEUTICALS INC
2005
Pursuant to 17 CFR 20.24b-2, confidential information has been omittedin places marked "***" and has been filed separately with the Securities and Exchange Commission pursuant to...
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2015
Exhibit A (ProprietaryInformation and Inventions Agreement) EMPLOYEES PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2014
Peramivir, a neuraminidase inhibitor for the potential treatment of influenza
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2011
Peramivir, a neuraminidase inhibitor for the potential treatment of influenza
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2011
John L. Higgins
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2010
John L. Higgins
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2010
Financial Statements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2009
Financial Statements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2009
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2008
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2008
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2008
AMENDMENT OF BIOCRYST
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2007
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
AL
2007